Powered by
-
AZN Stock Chart
Historical AZN Prices
ASTRAZENECA SP ADS Stock Analysis
Rating: Hold
Total Grade: C
Analysis Breakdown
| AZN Stock Grade: | C |
| Fundamental Grade: | C |
| Quantitative Grade: | C |
| AZN Earnings | |
| Earnings Growth: | D |
| Earnings Momentum: | C |
| Earnings Surprises: | D |
| Analyst Earnings Revisions: | D |
| AZN Financial Information | |
| Sales Growth: | D |
| Operating Margin Growth: | D |
| Cash Flow: | C |
| Return on Equity: | A |
ASTRAZENECA SP ADS Stock: Weekly View
| This Week: | C |
|---|---|
| Last Week: | B |
| Two Weeks Ago: | B |
AZN Stock predictions, Articles, and ASTRAZENECA SP ADS News
- From InvestorPlace
- From the Web
-
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs - May 18, 2018
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are. Continue…
-
AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales - May 18, 2018
AstraZeneca plc (AZN) stock was down on Friday following the release of its earnings report for the first quarter of 2018. Continue…
-
3 Emerging Technologies Set to Transform the Pharma World - April 5, 2018
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by.... Continue…
-
The Future of Merck & Co., Inc. Stock Is With Keytruda - February 5, 2018
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now. Continue…
-
The 5 Best Dow Jones Stocks to Buy for 2018 - January 10, 2018
Don't ignore Dow Jones stocks. They can still power your portfolio. Here are 5 of the best to own in 2018. Continue…
-
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy - December 1, 2017
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month. Continue…
-
Earnings Visibility Make AstraZeneca (AZN) a Buy - November 17, 2017
AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader places it 37 among the 132 companies in this industry group, giving it an above-average position. AZN is ranked in the top half of the sector with a ranking of 267 among the 782 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe. Continue…
-
AstraZeneca (AZN) Upgraded to Buy on Strong Quant Score - November 10, 2017
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical. Continue…
-
AstraZeneca (AZN) Upgraded to Buy from a Hold - November 3, 2017
AstraZeneca Plc (NYSE:AZN) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methods. The shares have been upgraded from a Hold to a Buy in the last week. Continue…
-
Earnings Growth Restricts AstraZeneca (AZN) Rating - October 27, 2017
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Hold. Using Louis Navellier's investing methodology, this analytical tool assesses stocks with fundamental and quantitative analytical tools. AZN has maintained this ranking for the last month. Continue…
